Koshinski Asset Management Inc. Has $580,000 Holdings in Pfizer Inc. (NYSE:PFE)

Koshinski Asset Management Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 29.7% in the fourth quarter, HoldingsChannel reports. The fund owned 20,135 shares of the biopharmaceutical company’s stock after selling 8,517 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Pfizer were worth $580,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new stake in Pfizer in the first quarter valued at approximately $29,000. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the third quarter valued at approximately $30,000. Sanctuary Wealth Management L.L.C. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $50,000. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer in the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on PFE shares. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 1st. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

Shares of PFE opened at $25.86 on Monday. The firm has a market cap of $146.43 billion, a PE ratio of 71.83, a PEG ratio of 1.16 and a beta of 0.61. The stock’s fifty day moving average price is $27.28 and its two-hundred day moving average price is $28.88. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.